Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-11-14
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 40
- Registration Number
- NCT00210028
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Institut Val d'Aurelle_ Paul Lamarque, Montpellier, France
🇫🇷Institut Claudius Regaud, Toulouse, France
Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 100
- Registration Number
- NCT00214110
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 3
- Registration Number
- NCT00206492
- Locations
- 🇺🇸
Baylor Breast Center, Houston, Texas, United States
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-10-24
- Lead Sponsor
- The Alfred
- Target Recruit Count
- 51
- Registration Number
- NCT00206544
- Locations
- 🇦🇺
Bayside Health - The Alfred Hospital, Melbourne, Victoria, Australia
Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- International Breast Cancer Research Foundation
- Target Recruit Count
- 740
- Registration Number
- NCT00201851
- Locations
- 🇲🇦
National Institute of Oncology, Rabat, Morocco
🇵🇭Vicente Soto Memorial Medical Center, Cebu, Philippines
🇵🇭East Avenue Medical Center, Manila, Philippines
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-07-20
- Lead Sponsor
- AGO Study Group
- Registration Number
- NCT00189358
- Locations
- 🇩🇪
Dept. of Gynecology, Evangelisches Krankenhaus, Duesseldorf, Germany
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 4
- Registration Number
- NCT00183963
- Locations
- 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 263
- Registration Number
- NCT00171704
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00165308
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
- Conditions
- Interventions
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 2411
- Registration Number
- NCT00002707
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.